Skip to main content

Articles

Conference Highlights ASH
Safety and Efficacy of Obinutuzumab (GA101) with Fludarabine Cyclophosphamide or Bendamustine in the Initial Therapy of Patients with Chronic Lymphocytic Leukemia: Results from the Phase 1b GALTON Trial
Read More
Conference Highlights ASH
Chronic Lymphocytic Leukemia: A New Treatment Era is Born
Read More
Conference Highlights ASH
Head-To-Head Comparison of Obinutuzumab Plus Chlorambucil versus Rituximab Plus Chlorambucil in Patients with Chronic Lymphocytic Leukemia and Coexisting Medical Conditions: Final Stage 2 Results of the CLL11 Trial
Read More
Leukemia, Oncology
Idelalisib Improves Outcomes in Heavily Pretreated Patients with CLL
Read More
FDA Approvals
Gazyva for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology
Read More
Conference Highlights ASH
Siltuximab: Monoclonal Antibody Relieves Symptoms of Castleman’s Disease
Read More
Conference Highlights ASH
More Transplants Made Possible Through Haploidentical Donors
Read More
Conference Highlights ASH
Hospital Readmission After Stem-Cell Transplant Decreases Survival
Read More
Conference Highlights ASH
JAK1/2 Inhibitor Ruxolitinib Improves Survival in High-Risk Myelofibrosis
Read More
Perspectives
Increasing Emphasis on Costs in the Management of Patients with Hematologic Cancers
Read More
Page 157 of 244
Results 1561 - 1570 of 2434